(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
'Heated Rivalry' is just the tip of the iceberg. How hockey became the sexiest sport - 2Schools to start reopening after Nigeria mass abduction
- 3Defence chiefs of Thailand and Cambodia to discuss ceasefire
- 4‘Democratizing space’ is more than just adding new players – it comes with questions around sustainability and sovereignty
- 5Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- The 12 biggest space stories of 2025 — according to you
- Supportive Tips On Home loans For First-Time Home Purchasers
- The many ways that baking is winter therapy. With a delicious ending
- Concern for couple jailed in Tehran as British embassy closes
- Understanding Successful Compromise Standards to Cultivate Agreeable Connections
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Conquering Language Boundaries: Individual Accounts of Multilingualism
- Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
